Avanos Medical Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $494.65 million. The enterprise value is $557.85 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.40 million shares outstanding. The number of shares has decreased by -0.65% in one year.
| Current Share Class | 46.40M |
| Shares Outstanding | 46.40M |
| Shares Change (YoY) | -0.65% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 91.94% |
| Float | 45.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.71 |
| PS Ratio | 0.70 |
| Forward PS | 0.71 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 1.89 |
| P/FCF Ratio | 6.60 |
| P/OCF Ratio | 4.74 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.39, with an EV/FCF ratio of 7.45.
| EV / Earnings | n/a |
| EV / Sales | 0.80 |
| EV / EBITDA | 7.39 |
| EV / EBIT | 15.76 |
| EV / FCF | 7.45 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.38 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 1.79 |
| Interest Coverage | 4.07 |
Financial Efficiency
Return on equity (ROE) is -46.68% and return on invested capital (ROIC) is 1.89%.
| Return on Equity (ROE) | -46.68% |
| Return on Assets (ROA) | 1.62% |
| Return on Invested Capital (ROIC) | 1.89% |
| Return on Capital Employed (ROCE) | 3.85% |
| Revenue Per Employee | $314,279 |
| Profits Per Employee | -$210,552 |
| Employee Count | 2,227 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | -19.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.51% in the last 52 weeks. The beta is 1.10, so Avanos Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -44.51% |
| 50-Day Moving Average | 11.71 |
| 200-Day Moving Average | 12.87 |
| Relative Strength Index (RSI) | 35.21 |
| Average Volume (20 Days) | 457,694 |
Short Selling Information
The latest short interest is 2.32 million, so 5.00% of the outstanding shares have been sold short.
| Short Interest | 2.32M |
| Short Previous Month | 3.19M |
| Short % of Shares Out | 5.00% |
| Short % of Float | 5.12% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $699.90 million and -$468.90 million in losses. Loss per share was -$10.15.
| Revenue | 699.90M |
| Gross Profit | 365.90M |
| Operating Income | 35.40M |
| Pretax Income | -487.90M |
| Net Income | -468.90M |
| EBITDA | 75.50M |
| EBIT | 35.40M |
| Loss Per Share | -$10.15 |
Full Income StatementBalance Sheet
The company has $70.50 million in cash and $133.70 million in debt, giving a net cash position of -$63.20 million or -$1.36 per share.
| Cash & Cash Equivalents | 70.50M |
| Total Debt | 133.70M |
| Net Cash | -63.20M |
| Net Cash Per Share | -$1.36 |
| Equity (Book Value) | 778.00M |
| Book Value Per Share | 16.77 |
| Working Capital | 203.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $104.40 million and capital expenditures -$29.50 million, giving a free cash flow of $74.90 million.
| Operating Cash Flow | 104.40M |
| Capital Expenditures | -29.50M |
| Free Cash Flow | 74.90M |
| FCF Per Share | $1.61 |
Full Cash Flow StatementMargins
Gross margin is 52.28%, with operating and profit margins of 5.06% and -67.00%.
| Gross Margin | 52.28% |
| Operating Margin | 5.06% |
| Pretax Margin | -69.71% |
| Profit Margin | -67.00% |
| EBITDA Margin | 10.79% |
| EBIT Margin | 5.06% |
| FCF Margin | 10.70% |
